Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia

<b><i>Background:</i></b> Well-differentiated neuroendocrine neoplasms (NENs) are usually controlled by antiproliferative, local ablative and/or radionuclide therapies, whereas poorly differentiated NENs generally require cytotoxic chemotherapy. However, treatment options for patients with advanced/metastatic high-grade NENs remain limited. <b><i>Method:</i></b> Review of the literature and...